Keywords: Amgen, Xgeva, Bone metastases, USA, FDA,CRL, sBLA

FDA stalls Amgen's Xgeva sBLA for prevention of bone metastases

Article | 30 April 2012

Print This

USA-based Amgen (Nasdaq: AMGN) revealed on Friday that the US Food and Drug Administration has issued a Complete Response Letter ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in